Chinese herbal medicine for the treatment of Henoch-Schönlein purpura nephritis in children: A prospective cohort study protocol

Jun Zhang, Jing Lv, Shuang Pang, Xiaohong Bai, Fang Yuan, Yubin Wu, Hong Jiang, Guanqi Yang, Shaoqing Zhang, Jun Zhang, Jing Lv, Shuang Pang, Xiaohong Bai, Fang Yuan, Yubin Wu, Hong Jiang, Guanqi Yang, Shaoqing Zhang

Abstract

Introduction: Henoch-Schönlein purpura nephritis (HSPN) involves the renal impairment of Henoch-Schönlein purpura and can easily relapse into life-threatening late nephropathy in severe cases. Although there is a lack of validated evidence for its effectiveness, Chinese herbal medicine (CHM) is one of the most commonly used methods in China to treat HSPN. It is thus need to report the protocol of a prospective cohort trial using CHM to investigate the effectiveness, safety and advantages for children with HSPN.

Methods and analysis: This large, prospective, multicenter cohort study started in May 2015 in Shenyang. Six hundred children diagnosed with HSPN were recruited from 3 institutions and are followed-up every 2 to 4 weeks till May 2020. Detailed information of participants includes general information, history of treatment, physical examination, and symptoms of TCM is taken face-to-face at baseline.

Ethics and dissemination: This study has received ethical approval from the ethics committee of institutional review board of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (No.2016CS(KT)-002-01). Articles summarizing the primary results and ancillary analyses will be published in peer-reviewed journals.

Trial registration: Clinical Trials Registration: NCT02878018.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Protocol for selection participants. CHM = Chinese herbal medicine, HSPN = Henoch–Schönlein purpura nephritis.

References

    1. Kawasaki Y, Ono A, Ohara S, et al. Henoch–Schönlein purpura nephritis in childhood: pathogenesis, prognostic factors and treatment. Fukushima J Med Sci 2013;59:15–26.
    1. Gardner-Medwin JM, Dolezalova P, Cummins C, et al. Incidence of Henoch–Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002;360:1197–202.
    1. Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch–Schönlein purpura in Taiwan. Rheumatology (Oxford) 2005;44:618–22.
    1. Saulsbury## FT. Clinical update: Henoch–Schonlein purpura. Lancet 2007;369:976–8.
    1. Sano H, Izumida M, Shimizu H, et al. Risk factors of renal involvement and significant proteinuria in Henoch–Schonlein purpura. Eur J Pediatr 2002;161:196–201.
    1. Bogdanović R. Henoch–Schönlein purpura nephritis in children: risk factors, prevention and treatment. Acta Paediatr 2009;98:1882–9.
    1. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch–Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 2006;149:241–7.
    1. Reinehr T, Burk G, Berger T, et al. Steroids for prophylaxis of nephropathy in Schnlein Henoch purpura? Follow-up of 171 patients [in German]. Klin Padiatr 2000;212:99–102.
    1. Huber AM, King J, McLaine P, et al. A randomized. placebo-controlled trial of prednisone in early Henoch Schönlein purpura [ISRCTN85109383]. BMC Med 2004;2:7.
    1. Saulsbury FT. Corticosteroid therapy does not prevent nephritis in Henoch–Schönlein purpura. Pediatr Nephrol 1993;7:69–71.
    1. Foster BJ, Bernard C, Drummond KN, et al. Effective therapy for severe Henoch–Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr 2000;136:370–5.
    1. Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch–Schönlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001;21:128–33.
    1. Jing H, Yan Y, Xin L, et al. Treatment of Chinese herbal washout combined with western medicine for 113 cases of skin type Henoch–Schonlein purpura [in Chinese]. J Trad Chin Med 2014;55:68–9.
    1. Ling WY, Ying W, Hou JF. Effects of herbal decoction orally combined with herbal fumigation and acupuncture therapy for children of Henoch–Schonlein purpura abdominalis [in Chinese]. Chin Pediatr Integr West Med 2016;8:512–3.
    1. Feng SY. Integrative medicine treatment of children with allergic purpura nephritis [in Chinese]. Chin Arch Trad Chin Med 2013;31:1718–20.
    1. Hong WJ, Ying D, Qing RX, et al. Effect of tripterygium glycosides and administration of Chinese medicine based on differentiation on the coagulation mechanism of Henoch–Schonlein purpura nephritis in children [in Chinese]. J Tradit Chin Med 2012;53:212–4.
    1. Rao HS, Na WX, Min CX, et al. Erythema elimination electurary clinical study as adjuvant therapy to treat anaphylactoid purpura [in Chinese]. Chin J Exp Tradit Med Form 2010;16:182–4.
    1. Qi YG, Qing ZS, Jun Z. Cooling blood and resolving toxin to transform stagnation methods in treating allergic purpura [in Chinese]. J Liaoning Univ TCM 2013;15:150–1.
    1. Jun Z, Qing ZS, Jun ZL, et al. Retrospective analysis of 257 cases of allergic purpura in children [in Chinese]. Chin Pediatr Integr Tradit West Med 2009;1:85–7.
    1. Ming ML, Yong ZH, Xin Z, et al. Analysis of the clinical use of professor Jun Zhang in treating pediatric allergic purpura based on data mining method [in Chinese]. J Liaoning Univ TCM 2016;18:88–90.
    1. Subspecialty Group of Renal Disease, the Society of Pediatrics, Chinese Medical Association. Clinical classification, diagnosis and treatment of glomerular diseases in children [in Chinese]. Chin J Pediatr 2001;39:746–9.
    1. Ling LG, Fu GY, Kun XZ, et al. The pathological analysis of 2551 children patients with glomerulopathy [in Chinese]. J Med Postgra 2011;24:294–7.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe